- Home
- STX vs BMY Comparison
STX vs BMY Comparison
Compare STX & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$584.00
HOLD
Current Price
$59.27
Company Overview
Basic Information| Metric | STX | BMY |
|---|---|---|
| Founded | 1978 | 1887 |
| Country | Singapore | United States |
| Employees | N/A | 32500 |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.7B | 123.7B |
| IPO Year | 2002 | N/A |
Fundamental Metrics
Financial Performance| Metric | STX | BMY |
|---|---|---|
| Price | $584.00 | $59.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 16 |
| Target Price | ★ $447.35 | $62.13 |
| AVG Volume (30 Days) | 3.2M | ★ 8.9M |
| Earning Date | 04-28-2026 | 04-30-2026 |
| Dividend Yield | 0.53% | ★ 4.24% |
| EPS Growth | ★ 328.48 | N/A |
| EPS | ★ 5.03 | N/A |
| Revenue | ★ $7,384,000,000.00 | N/A |
| Revenue This Year | $27.73 | N/A |
| Revenue Next Year | $25.06 | N/A |
| P/E Ratio | $110.93 | ★ $17.26 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $79.14 | $42.52 |
| 52 Week High | $567.70 | $62.89 |
Technical Indicators
Market Signals| Indicator | STX | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 73.52 | 51.27 |
| Support Level | $350.76 | $59.23 |
| Resistance Level | N/A | $62.39 |
| Average True Range (ATR) | 22.63 | 1.29 |
| MACD | 7.99 | 0.07 |
| Stochastic Oscillator | 92.32 | 64.08 |
Price Performance
Historical Comparison STX
BMY
About STX Seagate Technology Holdings PLC (Ireland)
Seagate Technology is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital; they are both vertically integrated.
About BMY Bristol-Myers Squibb Company
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.